Pay in 4 interest-free payments of $7.05 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Some patients find that tirzepatides dual mechanism produces a different side effect experience than semaglutides GLP-1 monoagonism
Side-by-Side Comparison Parameter Receptors Cagrilintide AMY1R/2R/3R + CTR Semaglutide GLP-1R Tirzepatide GLP-1R + GIPR Retatrutide GLP-1R + GIPR + Glucagon-R Parameter Half-life Cagrilintide ~7-8 days Semaglutide ~7 days Tirzepatide ~5 days Retatrutide ~6 days Parameter Dosing frequency Cagrilintide Once weekly Semaglutide Once weekly Tirzepatide Once weekly Retatrutide Once weekly Parameter Max studied dose Cagrilintide 4.5 mg/week (mono) Semaglutide 2.4 mg/week Tirzepatide 15 mg/week Retatrutide 12 mg/week Parameter Peak monotherapy weight loss Cagrilintide 11.8% at 68 wk Semaglutide 14.9-17% at 68 wk Tirzepatide 22.5% at 72 wk Retatrutide ~24% at 48 wk Parameter FDA status (June 2026) Cagrilintide Investigational Semaglutide Approved (2021) Tirzepatide Approved (2023) Retatrutide Investigational Parameter HbA1c reduction (T2D) Cagrilintide ~0.9 pp mono
Ajnlott adagols A javasolt napi mennyisg 1 kapszula, amelyet bsges folyadkkal rdemes bevenni
Ethics declarations Competing interests The following authors are advisors to the Reverse Aging Science Board at Parfums Christian Dior: D.F., J.A., G.C., K.J.A.D., A.D., V.N.G., B.K
